Fluvastatin

CHEMBL2220442 Phase 4 Approved Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
411.5 g/mol
LogP
3.5
Phase
4

This statin medication lowers LDL cholesterol and triglycerides by blocking the enzyme HMG-CoA reductase in the liver, which is responsible for cholesterol production. It reduces the risk of cardiovascular events in people with high cholesterol or established heart disease.

Molecular Weight

411.5000 g/mol

LogP

3.50

TPSA

82.70 Ų

Lipinski RO5

Pass

Therapeutic Areas

Mechanism of Action

Competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway of cholesterol biosynthesis. This reduces intracellular cholesterol, upregulates LDL receptor expression, and lowers circulating LDL cholesterol.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanism

Competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway of cholesterol biosynthesis. This reduces intracellular cholesterol, upregulates LDL receptor expression, and lowers circulating LDL cholesterol.

2D Structure

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(C)n1c(/C=C/C(O)CC(O)CC(=O)O)c(-c2ccc(F)cc2)c2ccccc21

InChI

InChI=1S/C24H26FNO4/c1-15(2)26-21-6-4-3-5-20(21)24(16-7-9-17(25)10-8-16)22(26)12-11-18(27)13-19(28)14-23(29)30/h3-12,15,18-19,27-28H,13-14H2,1-2H3,(H,29,30)/b12-11+

Molecular Formula

C24H26FNO4

HBD / HBA

3 / 5

Rotatable Bonds

8

Heavy Atoms

30

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

This statin medication lowers LDL cholesterol and triglycerides by blocking the enzyme HMG-CoA reductase in the liver, which is responsible for cholesterol production. It reduces the risk of cardiovascular events in people with high cholesterol or established heart disease.

Competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway of cholesterol biosynthesis. This reduces intracellular cholesterol, upregulates LDL receptor expression, and lowers circulating LDL cholesterol.

Yes, Fluvastatin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2220442. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 1548972. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.